Aurinia Pharmaceuticals Inc. — Biotechnology. Scored on the same transparent 7-signal model behind the daily rankings.
★
AUPH
Aurinia Pharmaceuticals Inc. · Biotechnology
FCF$167mC
Rev+20.4%A-
D/E0.12B+
P/E7.5xA
PEG0.38A
78.1Score
$16.59$2.1B
1Y Target$17.00Analyst consensus · 7 analysts
5Y Target$21.46Compound horizon
10Y Target$27.52Long-dated conviction
FCF$167mTTM · 03/26C
FCF $167m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+20.4%TTM YoYA-
Revenue +20.4% — strong growth, well above S&P median (~7%)
D/E0.12B+
D/E 0.12 — below the Healthcare debt median (≈40th pctile)
P/E7.5xA
P/E 7.5 — cheapest decile in Healthcare (≈10th pctile)
PEG0.38proxyA
PEG 0.38 — exceptional; paying well under fair value for growth · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 78.1
Quality0.82
Growth0.67
Value0.88
Why this score
Buying back stock
Earnings outpace cash
Entry · Margin of safety
52-week rangeNear 52-week high
14% off the 12-month high
vs DCF fair value14% belowest. fair value ~$19
Quality signals · context only
Gross profitability37% · B+gross profit ÷ total assets (Novy-Marx)
ROIC17.3% · A-return on invested capital — not score-weighted
Why now
Aurinia Pharmaceuticals is a compelling growth story, trading at a deep discount relative to its robust fundamentals and specialized market. With a TTM P/E of just 7.5 and an exceptionally low 0.37 PEG ratio, the market is significantly underpricing its ability to compound revenue at 20.4% YoY. The company's flagship product, LUPKYNIS, addresses a high unmet medical need in lupus nephritis, driving substantial free cash flow of $167m and an astounding 100% profit margin, which should continue to fuel expansion in the autoimmune disease market.
Moat
AUPH's durable edge stems from its specialized oral therapy, LUPKYNIS, for active lupus nephritis, a condition with high unmet medical needs, providing significant pricing power and market entrenchment in the United States and Japan. This focus on a specific, critical indication, coupled with intellectual property protection, underpins its remarkable 52.5% Return on Equity, making it difficult for competitors to quickly replicate its market position and profitability.
Risk
The primary bear case centers on concentration risk around LUPKYNIS and the inherent volatility of a biotechnology stock, reflected in its high 1.42 Beta. While the current product is strong, a lack of significant pipeline diversification beyond aritinercept for autoimmune diseases could expose Aurinia to future competitive pressures or clinical setbacks. The concrete signal confirming the bear case would be a failure in later-stage trials for aritinercept, or the emergence of a superior, widely adopted therapy for lupus nephritis.
Horizon
1-3 yr $17.00 (7-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $21.46 at ~5% CAGR — dividend + buyback compounding. 10 yr $27.52 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · AUPH
$
%
%
Shares to buy
120
Position size
$1,991
4.0% of portfolio
Stop price
$12.44
25% below $16.59
$ at risk if stopped
$497.70
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Aurinia Pharmaceuticals Inc. (AUPH): score, valuation & FAQ
Aurinia Pharmaceuticals Inc. (AUPH) is a Biotechnology company that scores 78.1 out of 100 on the Bull Rankings quality-growth model — a strong reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A), PEG (A) and Rev (A-). On valuation, AUPH sits about 14% below our discounted-cash-flow fair value (a margin of safety).
Is AUPH a good stock to buy?
Bull Rankings scores AUPH 78.1 out of 100 on its quality-growth model, which is a strong reading. That is driven by P/E (A), PEG (A) and Rev (A-). A score is a quantitative screen of Aurinia Pharmaceuticals Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does AUPH score 78.1 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). AUPH earns its highest marks on P/E (A), PEG (A) and Rev (A-). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is AUPH overvalued or undervalued?
Based on $16.59, AUPH sits about 14% below our discounted-cash-flow fair value (a margin of safety). It trades at a 7.5x× P/E (graded A). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in AUPH?
The primary bear case centers on concentration risk around LUPKYNIS and the inherent volatility of a biotechnology stock, reflected in its high 1.42 Beta. While the current product is strong, a lack of significant pipeline diversification beyond aritinercept for autoimmune diseases could expose Aurinia to future competitive pressures or clinical setbacks. The concrete signal confirming the bear case would be a failure in later-stage trials for aritinercept, or the emergence of a superior, widely adopted therapy for lupus nephritis.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.